Mahesh Mansukhani
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (15)
Year:
2026
Background JAK2, CALR, and MPL mutations are defining features of myeloproliferative neoplasms (MPNs). Molecular testing for variants in these genes is standard of care in the diagnosis of MPNs. A high reimbursement denial rate led to review of ordering practices and test utilization to identify potential areas for optimization, education, or triage to improve laboratory stewardship. Methods MPN panel orders placed between January 1, 2023 and December 31, 2023 were analyzed by ordering provider, complete blood count (CBC) values, demographics, test results, and International Classification of Diseases, 10th revision (ICD10) code. Laboratory staff manually review orders prior to testing. Clinical appropriateness was defined as unexplained cytosis or atypical thrombosis. Results Orders for 257 unique patients were included for analysis. Most orders were placed by hematology/oncology providers (79.0%). Of orders, 72.8% had a cytosis-related ICD10 code, and 11.7% a thrombosis-related ICD10 code. MPN panel results were negative in 76.3% of patients and positive (pathogenic mutations in JAK2/CALR/MPL) in 13.2%. A χ2 test did not show a statistically significant association between ICD10 category and positive results. Of patients with positive results, 79.4% had thrombocytosis on CBC, but 70.6% had normal or low hemoglobin. Conclusions Orders for our institution’s MPN panel are generally appropriate and placed correctly. Our findings do not support additional interventions or clinical decision support, utilizing features such as the patient’s CBC values or ICD10 codes, as likely to be of significant benefit. The limited reimbursement remains challenging, but we will continue to engage stakeholders to advocate for continued access.
Year:
2026
Background/Objectives: While the genomic landscape of primary lung carcinomas is well characterized, there is a relative scarcity of fusion data on corresponding central nervous system (CNS) metastases. This study aimed to elucidate the molecular profiles of CNS metastases to (1) assess the significance of a combined DNA–reflex RNA fusion testing approach and (2) compare the mutational landscape between patients who present initially [early (≤2 months)] with CNS metastases and those who develop CNS metastases thereafter [late (>2 months)]. Methods: We performed a retrospective search of CNS metastases of adenocarcinoma of probable lung origin interrogated by targeted DNA–reflex RNA next-generation sequencing (NGS). The DNA NGS panel included the driver mutations EGFR, BRAF, KRAS, MET, and ERBB2. RNA NGS included ALK, RET, ROS1, and MET. Additionally, mutational profiles were examined between those with early versus late CNS metastases. Results: Of the 58 patients, 44 (75.9%) had mutations or alterations, including 34 identified by DNA NGS [EGFR (n = 17; 50.0%), KRAS (n = 15; 44.1%), MET (n = 2; 5.9%)] and 10/24 by RNA NGS [ALK (n = 7; 70%), MET (n = 2; 20%), ROS1 (n = 1; 10%)]. Of all patients, 32 (55%) presented with early and 26 (45%) with late CNS metastases. Although patients with early metastases had worse survival compared to those with late metastases (p < 0.001), there were no statistically significant differences in the mutational profiles between the two cohorts. Conclusions: A significant proportion of CNS metastases without driver mutations identified by DNA NGS had targetable alterations identified by RNA NGS (10/24, 41.7%). In summary, a combined DNA with reflex RNA fusion testing approach plays a significant role in detecting and potentially managing CNS metastases. Comprehensive prospective studies are essential to elucidate the differences between early and late CNS metastases.
Year:
2025
Background/Objectives: To reduce the early mortality of light-chain amyloidosis (AL), earlier diagnosis is needed. To pursue this goal, we conducted a multicenter study screening for AL λ-type (NCT04615572) in subjects > 60 years of age with λ smoldering myeloma (SMM) or monoclonal gammopathy of undetermined significance (MGUS), a light-chain differential (dFLC, λ minus κ) > 23 mg/L, and no prior amyloid diagnosis. Methods: Variables included AL-related IGVL gene usage and clonal plasma cell cytogenetic abnormalities, such as t(11;14) or gain 1q, which are present in 75% of AL cases. Here, 9 out of 33 λ IGVL genes, accounting for 90% of AL λ cases, were considered to be AL-related. Bone marrow was obtained, plasma cell cytogenetics and next generation sequencing for IGVL genes were performed, and subjects with AL-related IGVL genes were screened for AL using tissue studies. Results: From 2021 to 2023, we enrolled 30 subjects (19 M/11 F) with a median age of 68.5 years old (IQR 64.3–73), 17 SMM and 13 MGUS, with a median of 6% marrow plasma cells (range, 3.5–40). Here, 11 SMM and 4 MGUS cases had t(11;14) or gain 1q; 10/17 SMM and 12/13 MGUS had AL-related genes, and AL was ultimately confirmed by tissue biopsy in 3 with SMM. SMM, AL-related IGVL genes, and t(11;14) or gain 1q were found in 6 SMM subjects, including the 3 with AL (3/6 vs. 0/16; p < 0.05, Fisher’s exact, two-tailed). Conclusions: These results justify a larger study screening for AL in SMM to develop a likelihood algorithm for AL using dFLC, IGVL gene usage, and the presence of t(11;14) or gain 1q.
Year:
2025
Summary and list of detected and reported alterations by alteration type (CNV, SNV/Indel) and assay (both assays, Central Lab (CL) or Assay H only, Pilot Lab only). For both detected and reported variants, positive percent agreement (PPA) with Pilot Lab and then CL as reference along with average percent agreement (APA), which is a weighted average of each PPA, were calculated.
Year:
2025
Scatter plots of continuous copy number results obtained from Central Lab (CL) or assay H and Designated Lab (DL) assay. The solid line demonstrates a Deming regression line, while the dashed line demonstrates the identity line. Black points denote variants which were reported by both assays, light green is for variants detected by both assays but not reported by at least one assay, and orange points denote variants that were only detected by CL. Circle is for variants detected by both assays. Triangle is for a variant detected by both assays but reported only by DL. Diamond is for a variant reported only by CL.
Year:
2025
Purpose: NCI selected a network of Clinical Laboratory Improvement Amendments–certified laboratories performing routine next-generation sequencing (NGS) tumor testing to identify patients for the NCI Molecular Analysis for Therapy Choice (NCI-MATCH) trial. This large network provided a unique opportunity to compare variant detection and reporting between a wide range of testing platforms. Experimental Design: Twenty-eight NGS assays from 26 laboratories within the NCI-MATCH Network, including the NCI-MATCH central laboratory (CL) and 11 commercial and 14 academic designated laboratories (DL), were used for this study. DNA from eight cell lines and two clinical samples were sequenced. Pairwise comparisons in variant detection and reporting between each DL and CL were performed for single-nucleotide variant, insertion and deletion, and copy-number variant classes. Results: We observed high concordance in variant detection between CL and DL for single-nucleotide variants and insertions and deletions [average positive agreement (APA) > 95.4% for all pairwise comparisons] but lower concordance for variant reporting after analysis pipeline filtering. We observed much higher agreement between CL and assays using amplification as the target enrichment method (84.2% 82%) except between CL and two assays (APA = 76.9% and 71.4%) due to differences in estimation of copy numbers. Notably, for all variants, differences in variant interpretation also contributed to reporting discrepancies. Conclusions: This study indicates that different NGS tumor profiling tests currently in widespread clinical use achieve high concordance between assays in variant detection. For variant reporting, observed discrepancies are mainly introduced during the bioinformatic analysis.
Year:
2025
Summary of detected and reported CNV alterations by assay (both assays, Central Lab (CL) or assay H only, Designated Lab (DL) assay only). For both detected and reported variants, positive percent agreement (PPA) with DL and then CL as reference along with average percent agreement (APA), which is a weighted average of each PPA, were calculated.
Year:
2025
Summary of detected and reported CNV alterations by assay (both assays, Central Lab (CL) or assay H only, Designated Lab (DL) assay only). For both detected and reported variants, positive percent agreement (PPA) with DL and then CL as reference along with average percent agreement (APA), which is a weighted average of each PPA, were calculated. Cytogenetics results for all concordance study samples and gene amplification measurements using different techniques: NGS, ddPCR, microarray and FISH
Year:
2025
A, Scatter plot of continuous VAF results between Central Lab (CL) or assay H and Pilot Lab. B, Scatter plot of continuous CN results. The large plot focuses on copy numbers up to 50, while the small inset shows the full range of CNV. The solid line demonstrates a Deming regression line, while the dashed line demonstrates the identity line. Black points denote variants which were reported by both assays, light green is detected but not reported by Pilot Lab, while orange points denote variants that were only detected by CL. Circle is for variants detected by both assays. Triangle is for a variant detected by both assays but reported only by DL. Diamond is for a variant reported only by CL.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Collaborators (25)
Anjali Saqi
Columbia University
Shuang Wang
Professor of Biostatistics
Columbia University
Glòria Garrabou
University of Barcelona
Wenjuan Zhang
Assistant Professor
Cedars-Sinai Medical Center
Noah Brown
Assistant Professor
University of Michigan Hospital
Alice Chen
Head, Early Clinical Trial Development Program
National Cancer Institute
Michael Miller
Assistant Professor of Pathology at CUMC
Columbia University Vagelos College of Physicians and Surgeons
Philippe Lemaitre
Columbia University Irving Medical Center
Lisa McShane
Associate Director, Division of Cancer Treatment & Diagnosis
National Cancer Institute
Kurenai Tanji
Professor
Columbia University
Szabolcs Szelinger
Research Assistant Professor
Translational Genomics Research Institute
Peining Li
Professor
Yale University School of Medicine
Michelle Afkhami, MD
Chief and Professor, Division of Molecular Pathology and Therapy Biomarkers
City of Hope
Marshall Horwitz
Professor
Washington University School of Medicine
Dario Ronchi
Associate Professor
University of Milan
Neal Lindeman
Vice Chair, Molecular Pathology and Laboratory Medicine
Weill Cornell Medicine
Liqiang Xi
Staff Scientist
National Institutes of Health
RAVINDRA KOLHE
Augusta University
Michio Hirano
Assistant/Associate/Full Professor
Columbia University Irving Medical Center
Benjamin Izar
Assistant Professor
Columbia University Irving Medical Center
Eric Konnick
Associate Professor
University of Washington
Catherine Shu
Columbia University Irving Medical Center
Zenta Walther
Associate Professor
Yale University School of Medicine
Giacomo Comi
Professore Ordinario
Università degli Studi di Torino
Antonia Ribes Rubio
Head of the Section of Inborn Errors of Metabolism
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Make your next move.
Prepare your application
Review drafts before you send them.